1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

 
• By John Davis

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.

Racing
Competition between first-line combinations for advanced RCC is intense • Source: Shutterstock

Competition among drugs vying for a leading position in the future advanced renal cell carcinoma market just got a little tougher, with Merck & Co. Inc. releasing more top-line data from the KEYNOTE-426 study showing a combination of its PD-1 inhibitor, Keytruda (pembrolizumab), with Pfizer Inc.'s tyrosine kinase inhibitor, Inlyta (axitinib), improved overall survival, PFS and ORR in the first-line treatment of condition.

The data were released Feb. 11, 2019, the same day Pfizer and EMD Serono (Merck KGAA) announced that their...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

ESMO 25: IO Faces Difficult Pathway For Cylembio In Melanoma

 
• By Alaric DeArment

The company presented detailed data at ESMO and said its Phase III trial might have reached statistical significance with a larger sample size.

ESMO 25: Merck & Co Raises Hopes in Ovarian Cancer

 
• By Kevin Grogan

The company breaks new ground with Keytruda for platinum-resistant ovarian cancer and unveils promising Phase II data on its Daiichi-Sankyo-partnered ADC raludotatug deruxtecan.

ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population

 
• By Dexter Jie Yan

Besting BeOne Medicines’ Tevimbra plus chemotherapy, interim results from the head-to-head HARMONi-6 study of Akeso's ivonescimab plus chemotherapy show the combo might have the longest PFS versus its single-target immuno-oncology competitors.

More from Anticancer

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By Kevin Grogan

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.

ESMO 25: Biokin/SystImmune’s BsADC Doubles ORR/PFS Vs Chemo In NPC

 
• By Xu Hu

Biokin/SystImmune’s anti-EGFRxHER3 ADC iza-bren achieved one primary and the key secondary objectives in a Phase III trial in Chinese patients with R/M NPC and its lower incidence of interstitial lung disease compared with other ADCs is also noteworthy.

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.